AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02798588 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: 18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)->8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
Study NCT03438019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrO2
Description: The PrO2 device is linked to a tablet via Bluetooth and provides the user with a graphic representation of their inspiratory effort throughout all of inspiration and real-time biofeedback. This device incorporates a standard 2mm leak to avoid glottal closure during maximal inspiration. The PrO2 provides measures of MIP (cmH2O), SMIP (PTU) and ID (seconds).
Study NCT03438019 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Threshold Inspiratory Muscle Trainer
Description: The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
Study NCT03438019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold Inspiratory Muscle Trainer
Description: The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
Study NCT01783886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
Study NCT01783886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
Study NCT01783886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser Photocoagulation
Description: Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
Study NCT03046641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous training
Description: Study group I (42 participants) received the continuous training.
Study NCT03046641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The interval training
Description: Study group II (40 participants) received the interval training.
Study NCT03555123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simdax
Description: Levosimendan2.5mg/ml
Study NCT03555123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simdax
Description: Levosimendan2.5mg/ml
Study NCT03305367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed pine nut oil
Description: Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.
Study NCT04979936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Study NCT04979936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous cholecystostomy
Study NCT00685386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Description: The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
Study NCT03436576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Serum 50%
Description: Instillation of 1 drop of Autologous Serum 50% four times a day
Study NCT01234558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13
Description: single IV dose
Study NCT01234558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLYX-13
Description: single IV dose
Study NCT02139891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy with MultiPoint Pacing
Study NCT02139891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with MultiPoint Pacing
Study NCT04237298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified vacuum-formed retainer covering the palete
Description: The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
Study NCT00685386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room air insufflation
Description: During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
Study NCT04237298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified vacuum-formed retainer covering the palete
Description: The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
Study NCT01879046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroplasty
Description: Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
Study NCT02547168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRhythm ZIO XT patch
Description: The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
Study NCT01626807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking School Bus
Description: Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
Study NCT01353417 — intervention group
Intervention type: OTHER
Intervention: In this observational study no study specific intervention is planned
Description: Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
Study NCT02652468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
Study NCT02652468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV over 24 hours starting prior to cyclophosphamide
Study NCT02652468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV for 2 days
Study NCT02652468 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total nodal irradiation
Description: Undergo total lymphoid irradiation
Study NCT02652468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
Study NCT02652468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
Study NCT02652468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
Study NCT02652468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT02652468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO or IV ONLY if graft cell content is over 1 x 10\^5 cells/kg ideal BW of the patient
Study NCT02652468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV ONLY if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the patient
Study NCT04495725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products
Description: We will randomize participants to one of the following four conditions for discounted vouchers: 1) a discounted voucher for a placebo soft-gel capsule product, 2) a discounted voucher for a high THC:low CBD soft-gel capsule product, 3) a discounted voucher for an equal THC:CBD soft-gel capsule product, or 4) a discounted voucher for a low THC:high CBD soft-gel capsule product. We will stratify randomization by history of cannabis use (no use in the past year, used in the past year and not near-daily or daily (used in the past year and \<20 days out of the last 30 days), near-daily or daily (>= 20 days out of the last 30 days) baseline opioid analgesic prescription (chronic opioid treatment vs. not chronic opioid use), and primary pain condition (neuropathy, not neuropathy). Chronic opioid treatment is defined as prescribed opioids ≥90 non-overlapping days in the past 182 days. Randomization will occur in blocks to ensure equal randomization over time.
Study NCT04495725 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products
Description: We will randomize participants to one of the following four conditions for discounted vouchers: 1) a discounted voucher for a placebo soft-gel capsule product, 2) a discounted voucher for a high THC:low CBD soft-gel capsule product, 3) a discounted voucher for an equal THC:CBD soft-gel capsule product, or 4) a discounted voucher for a low THC:high CBD soft-gel capsule product. We will stratify randomization by history of cannabis use (no use in the past year, used in the past year and not near-daily or daily (used in the past year and \<20 days out of the last 30 days), near-daily or daily (>= 20 days out of the last 30 days) baseline opioid analgesic prescription (chronic opioid treatment vs. not chronic opioid use), and primary pain condition (neuropathy, not neuropathy). Chronic opioid treatment is defined as prescribed opioids ≥90 non-overlapping days in the past 182 days. Randomization will occur in blocks to ensure equal randomization over time.
Study NCT03922087 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03229824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antiseptic occlusive dressing group
Description: A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
Study NCT05316831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Pneumococcal polysaccharides conjugated to CRM197 carrier protein
Study NCT04267172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surgical simulation training in primary Total Hip Arthroplasty
Description: The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.
Study NCT04267172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention: Surgical Resident Control Group
Description: Control Group
Study NCT04267172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention: Consultant and Fellow Comparator Group
Description: Comparator Group
Study NCT02242305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine Butylbromide - Tablet
Study NCT02242305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine Butylbromide - Capsule
Study NCT02411175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% ethanol
Study NCT02242305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02242305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00519415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue plate
Description: A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
Study NCT00519415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facemask
Description: An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
Study NCT00861315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin
Description: Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
Study NCT00861315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous amikacin
Description: 20 mg/Kg amikacin are administred intravenousely once a day during three days.
Study NCT00861315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo nebulization
Description: 0.9% saline solution is nebulized once a day during three days
Study NCT00861315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo infusion
Description: 0.9% saline is administered intravenousely once a day during three days
Study NCT00718887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
Study NCT00718887 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir/Entecavir
Description: Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
Study NCT03265431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-TPP
Description: Imaging with 18-F-TPP (18F-BFPET)
Study NCT03265431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-TPP
Description: Imaging with 18-F-TPP (18F-BFPET)
Study NCT00969735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein cryoablation
Description: A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
Study NCT00969735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein radiofrequency ablation
Description: Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter > 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
Study NCT02768428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Audio Media
Description: each arm spends 15 mins for watching the video or study the handbooks
Study NCT00492739 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vaccination with VZV vaccine
Description: Varicella vaccination 2 doses 2 months apart.
Study NCT03594422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQP1351
Description: HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
Study NCT02037568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fPER
Description: Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal.
Study NCT03837015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estring Vaginal Ring
Description: Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
Study NCT03837015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RepHresh Pro-B
Description: Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally
Study NCT01159314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baerveldt Device surgical Procedure
Description: Implant surgery
Study NCT03577054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBB Prompt
Description: Mobile app developed through user-centred design in phase 1 of this study
Study NCT03577054 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-Dose High Frequency training
Description: Participants will be encouraged to practice their HBB skills daily
Study NCT03577054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Dose High Frequency training
Description: Participants will be encouraged to practice their HBB skills daily
Study NCT04617847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120101
Description: WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
Study NCT03811743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brenner FIT
Description: Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
Study NCT03811743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: By Design
Description: Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
Study NCT02030795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disconnection group
Description: The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
Study NCT02030795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial Suction group
Description: The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
Study NCT04438642 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: shoulder finishline
Description: tooth will be prepared having shoulder finishline.
Study NCT04438642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: butt joint with bevel
Description: tooth will be prepared having butt joint with bevel finishline.